Rabia Ozden
Directeur/Membre du Conseil chez ADVERUM BIOTECHNOLOGIES, INC.
Fortune : 124 967 $ au 30/04/2024
Profil
Rabia Gurses Ozden is an Independent Director at Adverum Biotechnologies, Inc. She previously worked as the Executive Medical Director-Ophthalmology at Quark Pharmaceuticals, Inc. from 2011 to 2014.
She also held the position of Vice President & Head-Clinical Ophthalmology at GSK Plc.
From 2015 to 2018, she served as the Vice President-Clinical Research & Development at Beacon Therapeutics (USA), Inc. Dr. Ozden was an Assistant Professor at New York Medical College.
In 2019, she briefly served as the Chief Medical Officer at Nightstar Therapeutics Ltd.
From 2019 to 2021, she was the Chief Development Officer at Akouos, Inc. Currently, she is the Chief Medical Officer at Ocular Therapeutix, Inc. Dr. Ozden obtained her doctorate degree from Hacettepe University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
OCULAR THERAPEUTIX INC
0,02% | 31/03/2024 | 29 754 ( 0,02% ) | 124 967 $ | 30/04/2024 |
| 22/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Rabia Ozden
| Sociétés | Poste | Début |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Directeur/Membre du Conseil | 17/03/2022 |
Anciens postes connus de Rabia Ozden
| Sociétés | Poste | Fin |
|---|---|---|
| OCULAR THERAPEUTIX, INC. | Directeur Technique/Scientifique/R&D | 20/05/2024 |
| AKOUOS | Corporate Officer/Principal | 01/01/2021 |
| NIGHTSTAR THERAPEUTICS PLC | Directeur Technique/Scientifique/R&D | 01/12/2019 |
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Directeur Technique/Scientifique/R&D | 01/03/2018 |
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | 01/01/2014 |
Formation de Rabia Ozden
| Hacettepe University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GSK PLC | Health Technology |
| OCULAR THERAPEUTIX, INC. | Health Technology |
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
Akouos, Inc.
 Akouos, Inc. BiotechnologyHealth Technology Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA. | Health Technology |
